About the Event
The US biosimilar market is projected to grow from less than $10B in 2022 to more than $100B by 2029.* Biosimilars represent one of the most significant opportunities for reducing drug costs for consumers and the US health care market. They are disrupting the drug market and driving down cost for providers, payers and consumers.
Payors must have a strategy to capture maximum savings, influence prescriber behaviors and make the lowest cost options accessible to patients. As more specialty products lose market exclusivity over the next decade, the increase in both biosimilar and generic competition will have a material impact on the cost savings we can achieve.
During this webinar you will hear from CVS Caremark experts about:
- Biosimilars – what they are, why they matter for specialty costs and the biosimilar pipeline.
- Achieving low net cost for specialty through formulary strategies
- An overview of CVS Health’s investment in a viable biosimilar marketplace
*US. Biosimilars Market Analysis, Insights and Forecast, 2018-2029.